Global identification of circular RNAs in imatinib (IM) resistance of chronic myeloid leukemia (CML) by modulating signaling pathways of circ_0080145/miR-203/ABL1 and circ 0051886/miR-637/ABL1

Imatinib (IM), targeting of BCR-ABL1 tyrosine kinase, is currently one of the first-line choices in the treatment of chronic myeloid leukemia (CML). This study aims to explore the molecular mechanisms underlying IM resistance in CML treatment. 108 CML patients were recruited and grouped according to...

Descripción completa

Detalles Bibliográficos
Autores principales: Lu, Yao-hua, Huang, Zhong-yi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8591874/
https://www.ncbi.nlm.nih.gov/pubmed/34781898
http://dx.doi.org/10.1186/s10020-021-00395-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8591874/
https://www.ncbi.nlm.nih.gov/pubmed/34781898
http://dx.doi.org/10.1186/s10020-021-00395-z

Ejemplares similares